Aptose Biosciences Inc. logo
Aptose to Hold KOL Event and Corporate Update Thursday, June 2nd
May 12, 2022 10:00 ET | Aptose Biosciences, Inc.
Clinical Updates for HM43239 and Luxeptinib Poster Presentation for HM43239 is Scheduled for June 10th at EHA2022 Hybrid Congress SAN DIEGO and TORONTO, May 12, 2022 (GLOBE NEWSWIRE) --...
Aptose Biosciences Inc. logo
Aptose Reports Results for the First Quarter 2022
May 09, 2022 16:01 ET | Aptose Biosciences, Inc.
Expands HM43239 dose cohort at 160 mg Headway with luxeptinib “G3” formulation in patients Conference call and webcast at 5:00 pm ET today SAN DIEGO and TORONTO, May 09, 2022 (GLOBE NEWSWIRE) --...
Aptose Biosciences Inc. logo
Aptose to Present at 2022 RBC Capital Markets Global Healthcare Conference
May 03, 2022 07:30 ET | Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, May 03, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly...
Aptose Biosciences Inc. logo
Luxeptinib Preclinical Data Extend Potential Applications from Oncology to Inflammation
May 02, 2022 16:10 ET | Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, May 02, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly...
Aptose Biosciences Inc. logo
Aptose Announces Executive Management Changes
April 07, 2022 07:00 ET | Aptose Biosciences, Inc.
─ Appoints Philippe Ledru as Chief Commercial Officer ─ ─ Announces resignation of CFO/CBO Jotin Marango, MD, PhD ─ SAN DIEGO and TORONTO, April 07, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences...
Aptose Biosciences Inc. logo
Aptose to Present at Canaccord Genuity’s 2022 Horizons in Oncology Virtual Conference
March 31, 2022 07:30 ET | Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, March 31, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly...
Aptose Biosciences Inc. logo
Aptose Reports Results for the Fourth Quarter and Full Year 2021
March 22, 2022 16:01 ET | Aptose Biosciences, Inc.
- HM43239 clinical remission at 120mg expands list of potential treatable AML populations - - On track to initiate genotype-enriched expansion program for HM43239 in 2H22 - - Cash runway...
Aptose Biosciences Inc. logo
Aptose to Report Fourth Quarter and Full Year 2021 Financial Results and Hold Conference Call on Tuesday, March 22, 2022
March 08, 2022 07:30 ET | Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, March 08, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical stage precision oncology company developing highly differentiated oral kinase...
Aptose Biosciences Inc. logo
Aptose to Present at Oppenheimer’s 32nd Annual Healthcare Conference
March 01, 2022 07:30 ET | Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, March 01, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the...
Aptose Biosciences Inc. logo
Aptose to Hold Corporate Update Monday, December 13th
November 29, 2021 07:30 ET | Aptose Biosciences, Inc.
HM43239 clinical update in AML after oral presentation at 2021 ASH Annual MeetingLuxeptinib clinical update in AML and B-cell cancers SAN DIEGO and TORONTO, Nov. 29, 2021 (GLOBE NEWSWIRE) -- Aptose...